Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Key 2022 Coding & Billing Updates

From the College  |  January 23, 2022

In 2022, rheumatology practices should prepare for documentation, coding, billing and reimbursement revisions related to evaluation and management (E/M), split/shared billing policies and telehealth services.

Risankizumab Effective Against Refractory Psoriatic Arthritis

Matthew Phelan  |  January 22, 2022

NEW YORK (Reuters Health)—Risankizumab, an inhibitor of interleukin (IL) 23, provides some relief for patients with active psoriatic arthritis (PsA) whose symptoms have responded poorly to standard treatments, according to 24-week results of a phase-3 trial. “Despite the range of available therapies for psoriatic arthritis, efficacious, well-tolerated therapeutic options are needed to treat the diverse…

Lab Study Suggests Zinc May Worsen Rheumatoid Arthritis

Marilynn Larkin  |  January 22, 2022

NEW YORK (Reuters Health)—Zinc supplementation may exacerbate rheumatoid arthritis (RA), new laboratory data suggest. In monocytes from patients with RA, researchers found high concentrations of intracellular zinc, which regulates immune responses by affecting signaling pathways, according to a report in Science Signaling.1 They also found increased expression of Zip8, a zinc-specific importer, in peripheral and…

ACR Insurance Subcommittee Chair Encourages Member Engagement

Carina Stanton  |  January 20, 2022

Rheumatology practices have a voice in payer advocacy through the Insurance Subcommittee of the ACR’s Committee on Rheumatologic Care.

Electronic Consultations Could Improve Access to Rheumatologic Care

Samantha C. Shapiro, MD  |  January 20, 2022

Patients shouldn’t need to exercise patience when it comes to getting needed rheumatologic care. E-consults are an evolving telehealth modality with the potential to improve access to rheumatologic care in a cost-effective and efficient manner.

Insights into JAK Inhibitor Use

Michele B. Kaufman, PharmD, BCGP  |  January 20, 2022

According to a German study presented during ACR Convergence 2021, treatment persistence with JAK inhibitors is comparable to TNF inhibitors and other bDMARDs among patients with rheumatoid arthritis.

Defining Administration Complexity by the Drug, Not the Diagnosis

Mary Beth Nierengarten  |  January 10, 2022

Enabling rheumatology practices to use complex administration codes for biologic drugs is critical for maintaining patient access to essential therapies.

The Power of Advocacy

Blair Solow, MD  |  January 10, 2022

In 1916, a handful of conservation advocates successfully lobbied Congress to create the National Park Service, which now protects more than 85 million acres of U.S. land. Dedicated rheumatology advocacy has lasting effects, too, as evidenced by several policy wins in 2021 and efforts underway for 2022.

Supporting Rheumatologic Care for Pediatric Patients

Mary Beth Nierengarten  |  January 10, 2022

As chair of the Pediatric Rheumatology Special Committee, Colleen Correll, MD, MPH, is supporting efforts to increase the pediatric rheumatology workforce as a whole and pediatric rheumatology representation in the ACR.

Ethics Forum: Vaccine Mandates

The ACR Committee on Ethics & Conflict of Interest  |  January 10, 2022

With the ongoing COVID‑19 pandemic, several tools and strategies have been developed and implemented to reduce the spread of disease. These include social distancing, adequate ventilation, masks, monoclonal antibody treatment and vaccination.1 As of December 2021, 60% of all Americans have been fully vaccinated, and 8 in 10 adults in the U.S. have received at…

  • « Previous Page
  • 1
  • …
  • 115
  • 116
  • 117
  • 118
  • 119
  • …
  • 816
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences